Sign inJoin waitlistJoin the waitlist

David Dunkin

Associate Professor of Pediatrics, Division of Pediatric Gastroenterology · Icahn School of Medicine at Mount Sinai

Credentials: · · · ·

History

Icahn School of Medicine at Mount Sinai
Present

Pediatric Gastroenterology
Mount Sinai Hospital
2005–2008
Yale New Haven Children's Hospital
2002–2005
Univ of California, San Francisco Sch of Med
1998–2002
Cornell University

Research

Skin exposure promotes a Th2-dependent sensitization to peanut allergens
Journal of Clinical Investigation · 2014 · 169 citations
Complex Autoinflammatory Syndrome Unveils Fundamental Principles of JAK1 Kinase Transcriptional and Biochemical Function
Case report · Immunity · 2020 · 109 citations
Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center
Journal of Pediatric Gastroenterology and Nutrition · 2019 · 101 citations

Xiu-Min Li
12 papers
KB
Keith Benkov
10 papers
JL
Joanne Lai
9 papers
HS
Hugh Sampson
8 papers
MD
Marla Dubinsky
8 papers
NP
Nanci Pittman
7 papers
Michael Dolinger
5 papers · 3 as a fellow
Alina Iuga
4 papers · 2 as a resident
Jacqueline Jossen
4 papers · 1 as a fellow
CC
Clare Ceballos
3 papers
ES
Elizabeth Spencer
3 papers · 1 as a fellow
Rachel Miller
3 papers

Grants

Epicutaneous Tolerance Induction with Flagellin Epitopes for the Treatment of Colitis
National Institute of Diabetes and Digestive and Kidney Diseases · R03
Contact PI · $169.5K · Icahn School of Medicine at Mount Sinai
2018–2020
Epicutaneous Tolerance Induction for the Treatment of Colitis
National Institute of Diabetes and Digestive and Kidney Diseases · K08
Contact PI · $634.8K · Icahn School of Medicine at Mount Sinai
2015–2019

Clinical trials

Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease
Principal investigator · Active not recruiting · Phase 1
Icahn School of Medicine at Mount Sinai
2023–2026
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2024–2028
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2021–2030